Stereotactic Body Radiotherapy

Questions discussed in this category

What dose would you recommend? Is SBRT needed?

What radiation dose and fractionation schedule do you use to treat atypical carcinoid tumors in patients who are medically inoperable?

Would you offer SBRT over standard fractionation of smaller tumors?

2 Answers available

What are reasonable SBRT dose constraints for the lumbosacral plexus?

In treating an oligometastatic lesion in the sacrum, is it reasonable to extrapolate from RTOG brachial plexus contraints (eg, 8 Gy/fx for a 3-fractio...

4 Answers available

Are there any situations where you would not offer SBRT for an oligometastatic bone lesion from breast cancer?

Is the dose fractionation used in BR-001 (10Gyx3) appropriate for all osseous locations, for example humeral head metastases?

1 Answer available

Do you offer SBRT Liver for patients with low platelets?

If so what is the crietria?

1 Answer available

Would you use SBRT to treat a >5cm NSCLC with chest wall invasion in a medically inoperable patient?

3 Answers available

What is the best SBRT dose-fractionation scheme for oligometastatic disease in the adrenal gland?

2 Answers available

For unresectable typical carcinoid what is the appropriate radiation regimen?

When is SBRT appropriate? Do you approach dose and fractionation differently in this setting?ƒ

1 Answer available

What is an acceptable distance between tumor and heart or aorta to treat a non-small cell lung cancer with SBRT?

Would close proximity to the heart/aorta affect your dose and fractionation?

4 Answers available

Would you treat an inoperable <5 cm NSCLC tumor involving the hilum with SBRT?

What fractionation scheme would you use? Would you give SBRT to a hilar tumor that has N1 nodal involvement adjacent to the tumor but can be enc...

4 Answers available

Do you use minimum cutoff values for any PFTs below which you would not offer conventionally fractionated chemoradiation or SBRT for NSCLC?

Are pre-treatment PFTs actually correlated with treatment-related toxicity? If no absolute cutoff, do you have an ideal lower limit for PFTs...

3 Answers available

For a patient with a solitary kidney, what dose constraints would you use for SBRT to a nearby site?

2 Answers available

What are your policies/practices for physician role of SBRT/SABR treatment delivery?

0 Answers available

How would you treat a patient with a solitary prostate cancer metastases in the mandible?

Would you consider SBRT and if so what dose/fractionation would you use if the lesion was in the head of the mandibula? If not would you give a fract...

2 Answers available

What is your thought process for dose prescriptions when treating abdominal/pelvic lymph node oligometastasis with SBRT?

For that occasional "single lymph node metastasis" referral in patients with no other sites of disease, is there a therapeutic dose below which you're...

5 Answers available

Should lung SBRT fractions be delivered on consecutive days, every other day, or perhaps an even more prolonged schedule?

Does tumor location play a role (central vs peripheral) in making the decision? The question stems from an oral presentation at ASTRO 2014 inves...

7 Answers available

Would you offer SBRT to a biopsy proven T1 renal cell carcinoma on a transplanted kidney?

1 Answer available

How would you approach potential SBRT to liver metastases in a patient on a VEGF inhibitor?

Would you alter your SBRT dose? How long would you hold the VEGF inhibitor before and after? Does the primary matter (e.g. NSCLC vs. colorectal)?

1 Answer available

When is SBRT or hypofractionated radiation appropriate as adjuvant treatment for pancreatic cancer?

What are the targets (tumor bed, positive margin, nodes etc.)?

4 Answers available

How would you manage a patient with oligometastatic disease in the femoral head?

Would this location be adequate for SABR, if so what dose scheduling would be recommended?

1 Answer available

Should special precautions be taken when treating oligometastatic disease in the sacrum or pelvis with SBRT in a patient with a long life expectancy?

For example in a patient with a good performance status and a biologically favorable cancer (ER+ breast cancer, EGFR+ NSCLC, or prostate cancer), are ...

1 Answer available

Would you use SBRT to treat a lipoma of the spine that recurred twice after surgery?

1 Answer available

Do you deliver prostate SBRT every other day or consecutively?

Is there a benefit to one fractionation schedule v. the other?

3 Answers available

Do you place any constraint on Dmax when developing plans for linac-based SRS or SBRT?

3 Answers available

Do you ever consider small vessel doses when determining your dose for SBRT?

For example, would you modify your SBRT dose next to the azygous vein? While we talk frequently about OAR constraints for the great vessels, it seems ...

1 Answer available

Do you ever consider a dose constraint to the spleen when treating lung tumors with stereotactic radiotherapy?

I am treating a left lower lobe NSCLC and my PTV is so close to the spleen that a small portion of the spleen is getting significant dose. I can...

3 Answers available

What follow-up imaging do you recommend after SBRT/SABR for lung cancer?

And at what intervals?

4 Answers available

Is it safe to deliver SBRT to progressive lung metastases to patients with metastatic RCC receiving concurrent pazopanib?

2 Answers available

Do you have a size criteria when treating lung oligometastases with SBRT?

Would you consider treating 3-5mm lesions with SBRT or wait until they are a certain size? I am concerned I will not be able to see them adequately on...

4 Answers available

What dose constraint do you use for the proximal bronchial tree for when treating NSCLC to 60 Gy/8 fx?

I see the LungTECH trial dose constraints, but, they seem really conservative when you have something large and close the PBT resulting in use of 60 G...

2 Answers available

Is there a current 'standard of care' dose and fractionation in treating lung cancer with SBRT?

There seem to be a lot of different fractionation schemes in the literature. Is there one that is most standard?

4 Answers available

When do you choose motion management over free-breathing techniques for lung SBRT?

Do you prefer breath-hold techniques (ABC, DIBH) or abdominal compression regardless of tumor motion? Or do you use a general threshold number of cc's...

1 Answer available

Is there really substantial evidence to avoid central lesions for SBRT?

The Indiana report and RTOG published a "danger zone". There was a catastrophic "case report" for 50 Gy in 5 fractions. Are there alternat...

5 Answers available

How do you determine dose for prostate SBRT?

Is there a dose response relationship, as suggested in the phase I MSKCC dose escalation study presented at ASTRO 2017?

2 Answers available

What potential risks of SBRT do you counsel patients on when treating early stage lung cancer with an underlying chronic lung infection?

In a patient with a cavitated lesion with underlying chronic infection (identified as cocci) and SqCC, are there additional risks to SBRT? Should spec...

1 Answer available

How do you manage a stage I LLL medically inoperable lung cancer in close proximity to the stomach?

In patients with aberrant anatomy due to previous surgery with lung PTV overlapping the stomach, how much would you dose de-escalate? Even conventiona...

2 Answers available

Is there concern for hemorrhage after SBRT to a lung metastasis that directly involves a branch of the pulmonary artery?

What dose and fractionation would you consider if surgery is not an option?

1 Answer available

How do you counsel patients in regards to the options and risks for salvage lobectomy/wedge after SBRT?

Do you discuss this at the first consultation? Is there strong evidence to suggest that risks are significantly increased compared to upfront lobectom...

1 Answer available

Is surgery preferable over SBRT for peripheral NSCLC invading into ribs?

Is local control worse for SBRT when the tumor is invading into the bone (rib)?

4 Answers available

Does the presence of interstitial lung disease affect your decision to offer SBRT for early stage NSCLC?

Specifically in O2-dependent patients? Have any dose/fractionation regimens been shown to reduce the risk of pneumonitis in this population?

6 Answers available

What factors do you use to decide between phase based vs. amplitude based gating for lung SBRT?

1 Answer available

How do you treat radiation myelopathy?

Aside from steroids and PT, is there anecdotal evidence for warfarin, hyperbaric oxygen, bevacizumab etc. Any experience with these therapies?

2 Answers available

Does proximity to or involvement of the aorta effect the dose and fractionation you use for an early stage NSCLC?

For example, a NSCLC of the LLL abutting and potentially involving the adventitia of the descending aorta?

1 Answer available

How do you manage chest wall pain due to SBRT?

In a patient with pain that does not respond well to narcotics what would be your treatment approach? Is there any data that suggests patients c...

1 Answer available

How do you treat inoperable T1-2N0 apical lung cancers near the brachial plexus but without extension outside the lung?

Is it possible to do SBRT?

4 Answers available

Is is okay to offer SBRT for central lung tumors in direct contact with the esophagus?

If so, 50 Gy / 5 fx? 7.5 Gy / 8 fx? If so what dose constraints would you use to help determine fractionation?

2 Answers available

Do you prescribe prophylactic steroids with spine SBRT?

Does fractionation (or location) influence this decision? What is your preferred steroid dose?

2 Answers available

What criteria do you use when selecting a multi-fraction vs single fraction approach for treatment of spine metastases with radiosurgery?

1 Answer available

How do you approach a peripheral, T1 lung cancer with a positive mediastinal node by EBUS?

Is there a role for SBRT to the primary site? Is it required to treat the ipsilateral hilum if no adenopathy was seen on EBUS or PET?

2 Answers available

Is 10 Gy x 5 an acceptable dose to use for lung SBRT in tumors with favorable location (eg. not central and not encroaching on the chest wall?)

Given the multiple retrospective studies showing benefit to higher BED fractionation schedules (most recently, http://www.redjournal.org/article/S0360...

2 Answers available

How would you approach treatment of an early-stage lung cancer adjacent to a prior lung cancer previously treated with SBRT?

Is another course of SBRT possible? If so, what are the important planning considerations?

1 Answer available

Do you treat adenocarcinoma in situ (AIS) or minimally invasive adenocarcinoma (MIA) of the lung with SBRT in medically inoperable patients?

Given the lepidic growth pattern, do you use similar margins as with frankly invasive lung tumors? Are there any challenges localizing the target with...

1 Answer available

Is there a firm rib dose constraint when treating lung tumors abutting the visceral pleura/chest wall with SBRT?

When treating lung tumors abutting the visceral pleura/chest wall with SBRT, chest wall or rib pain sometimes occurs. In these cases, I try to avoid i...

2 Answers available

What sites for SBRT are thought to be more immunogenic for antigen presentation when combined with immunotherapy?

If given options of liver, lung, spine, brain, axilla, or other lymph nodes which sites do you pick?

1 Answer available

Would you recommend post-operative radiation to an oligometastatic subcutaneous lesion resected with positive microscopic margins?

If so, how would you approach treatment?

1 Answer available

What cumulative dose constraints would you use for the normal liver when repeating SBRT for liver metastases with a longer time interval (i.e. 2-3 years)?

Do you factor in the time interval when deciding cumulative dose constraints?

1 Answer available

Is SBRT appropriate for a small endobronchial tumor distal to the proximal bronchial tree?

Any special dosing considerations or can you approach this like any other small peripheral NSCLC?

1 Answer available

How do you follow patients after SBRT for NSCLC?

Which imaging studies do you perform and what is the timing after treatment?

2 Answers available

When is it appropriate to recommend SBRT directed to sites of oligometastasis (ex, single adrenal met) for a patient with extensive stage small cell s/p chemo and PCI?

3 Answers available

Are there instances where you prefer a SBRT boost rather than a brachytherapy boost when treating definitive locally advanced cervical cancer?

If so, what dose/ volume is prescribed? How do you account for motion?

1 Answer available

Is there evidence to suggest that SRS/SBRT for spine or bone metastases provides faster and more durable palliative relief or soft tissue decompression than a fractionated course?

1 Answer available

What is the appropriate target volume for SBRT to a non-vertebral osseous metastasis?

Does your volume change based on fractionation (high-dose single fraction vs. 3-5 fractions)? Do you treat the entire circumference of long bones? Wha...

1 Answer available

Are the conformality constraints still important when organ at risk constraints are met for lung SBRT?

Are there specific conformality parameters you prioritize (105% dose volume outside of PTV, conformality index, ratio of 50% isodose volume to PTV, an...

2 Answers available

Should density overrides for VMAT lung SBRT planning be utilized for small mobile tumors?

Recently, while planning a patient for lung SBRT it was suggested by the physicist that we change the density of the PTV to higher density to improve ...

3 Answers available

What dose constraint, if any, do you use for the diaphragm when treating liver or lung tumors with SBRT?

Have you ever seen toxicity related to diaphragm dose with conventional fractionation?

4 Answers available

What surveillance imaging is appropriate after spine SBRT?

And at what intervals? The published trials/RTOG call for q3 month MRI follow-up. Is this appropriate outside a clinical trial setting?

2 Answers available

How do you treat a radioresistant (e.g. RCC or melanoma) oligometastases in a weight-bearing bone after surgical resection and stabilization?

If surgical stabilization has been performed, do you go with SBRT dosing? If so, do you treat only the involved site and not the extent of hardware? D...

1 Answer available

How do you manage a rib fracture caused by SBRT?

What is the average healing time? What medications and/or procedures do you recommend for pain control? Does management differ for those with chest wa...

1 Answer available

How do you best communicate SBRT planning directives, specifically in regard to how "hot" the plan should be?

Do you specify an isodose line to prescribe to? Do you ask for a percent hot, and if so do you specify what percent or volume of the GTV/ITV should re...

2 Answers available

Do you prescribe steroids prior to each fraction of lung SBRT?

Under what clinical circumstances would you consider prescribing them?

3 Answers available

Is there a standard spinal SBRT dose regimen for patients with "oligometastatic" disease being treated with curative intent?

Do you use the same regimen for primary treatment, re-treatment, and post-op?

2 Answers available

Would you utilize SRS/SBRT in a patient with oligometastatic disease from adenocarcinoma of the lung who is unable to receive standard chemotherapy?

For example, in a patient minimal brain and liver metastasis, would you treat all sites definitively?

2 Answers available

What are your criteria to determine if there is a local failure versus post treatment changes after SBRT for inoperable early stage NSCLC?

If a biopsy carries a high risk of morbidity what interventions would you recommend for the local failure?

4 Answers available

Is there an "ideal" method for abdominal motion control when treating upper abdomen malignancies?

In my training, we used an abdominal compression paddle, but in my current practice, my physicist says that we cannot treat through multiple parts of ...

1 Answer available

For T1b or T2a NSCLC cancer, approached with SABR, should chemotherapy be considered in the adjuvant setting?

As it is suggested for larger tumors treated with surgery, based on post hoc CALGB analysis?

2 Answers available

Do you use the PET scan hypermetabolic lesion to help contour the GTV for lung SBRT, especially in setting of peripheral atelectasis?

If so, how? Or would you avoid SBRT in such a situation?

1 Answer available

For early stage NSCLC to be treated with SBRT, is there any difference in the technology being used such as robotic v. linac based VMAT?

3 Answers available

What are the most common errors that can be made when performing prostate SBRT?

In starting prostate SBRT at an instutution, what are issues with the treatment that one should pay special attention to?

2 Answers available

Given the recent pooled analysis of STARS and ROSEL trials, can we say SBRT for early stage NSCLC is equivalent to lobectomy based on level 1 evidence?

Will the NCCN guidelines change based on this study?

2 Answers available

Do you treat supraclavicular metastasis with SBRT?

If so what dose-fractionation do you use and what constraints for brachial plexus?

1 Answer available

Do you require a biopsy prior to SBRT for pulmonary metastases from oligometastatic disease?

Specifically from a GI primary?

3 Answers available

When should SBRT be preferred in operative patients who cannot undergo a lobectomy?

In other words, if offered wedge or segmentectomy, should SBRT be preferred? Does size matter ie if the lesion is < 3 vs < 2 vs < 1 cm? Does ...

2 Answers available

For 5 fraction lung SBRT, is 11 Gy per fraction superior to 10 Gy per fraction?

The BED10 for 50 Gy in 5 fractions is 100, which is significantly lower then the BED of the 54 Gy in 3 fractions regimen (151). Since the Kestin/Grill...

2 Answers available

What is the clinical significance of R50 in lung SBRT?

Our dosimetrists rarely meet the RTOG constraint using a non-coplanar technique, especially for very small lesions. I haven't been able to find a corr...

2 Answers available

When should SBRT be offered to oligometastatic bone disease in a patient with prostate cancer?

What factors should be considered with offering SBRT to oligometastatic bone disease in prostate cancer patients? Should this been done off of a proto...

2 Answers available

What is the biggest mistake people make when starting a linac SRS program?

Any advice on how to safely incorporate it into our practice?

2 Answers available

What is an acceptable SBRT dose for a central lung cancer encasing a coronary artery bypass graft?

Would you consider placing a stent in this patent graft to minimize closure of the graft after SBRT?

1 Answer available

How do you approach lung tumors with vessel encasement, especially in someone with active hemoptysis?

Is there any concern about hemorrhage from treatment effect on tumor? Would SABR worsen the chance of fatal hemorrhage/hemoptysis and if so, would you...

1 Answer available

How do you approach volumes and dosing when using SBRT for a biopsy-proven NSCLC lung nodule with a central solid component and surrounding ground glass opacity (GGO) appearance?

For small overall volumes (e.g. 0.5cm solid component, 1cm total lesion size when including GGO), I imagine treating the entirety of the abnormality i...

4 Answers available

For which patients with localized prostate cancer is SBRT an alternate standard of care?

1 Answer available

What are your criteria for treating a patient with lung SBRT in the absence of a biopsy?

Roughly what percentage of patients are treated without a biopsy?

1 Answer available

Is it acceptable to use SBRT for prostate bed RT?

If so, what dose?

2 Answers available

Is local failure following SABR higher then previously thought?

ASTRO 2014's lung session presented data from RTOG 0236, showing a 20% intralobar failure/recurrence despite only 7% local failure. How does one recon...

1 Answer available

Is 3D non-coplanar conformal radiotherapy preferable over arc therapy for lung SBRT?

RTOG 0915 allows either technique, but I've heard people say that IMRT is not "technically" SBRT. Is there is a benefit to the non-coplanar 3D techniq...

3 Answers available

What is the best management for a local recurrence for a stage I NSCLC treated previously with SBRT?

Should fractionated EBRT be administered or can repeat SBRT be used?

1 Answer available

What clinical factors help you to determine whether or not a patient is an appropriate candidate for spine SRS/SBRT in the setting of metastatic disease?

1 Answer available

In SBRT for lung tumors, does Monte Carlo dose calculation algorithm versus AAA dose calculation give a better representation of lung target dose and normal tissue dose?

In SBRT, it has been said that Pencil Beam dose calculation algorithm can overestimate the target dose and understimate the normal tiss...

1 Answer available

When is it appropriate to use SBRT in treating lung metastases (oligomet, up to 3 mets etc.?)

What dose/fractionation is appropriate and does it differ between histology?

1 Answer available

How were decisions made about what dose constraints to use in the recent RTOG protocols for lung SBRT?

What are the primary data that drove organ at risk and conformality dose constraints?

1 Answer available

What fractionation and dose constraints do you use for prostate SBRT?

1 Answer available

What is the biggest mistake people make when performing lung SBRT?

1 Answer available

Papers discussed in this category

J Thorac Oncol, 2007 Jul

Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2014-03

Dose-response relationship with clinical outcome for lung stereotactic body radiotherapy (SBRT) delivered via online image guidance.

Int J Radiat Oncol Biol Phys, 2002 Mar 15

Clinical outcomes of 3D conformal hypofractionated single high-dose radiotherapy for one or two lung tumors using a stereotactic body frame.

Radiat Oncol, 2007 Jun 7

Exceptionally high incidence of symptomatic grade 2-5 radiation pneumonitis after stereotactic radiation therapy for lung tumors.

International journal of radiation oncology, biology, physics, 2012-02-01

Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer.

JAMA, 2010-03-17

Stereotactic body radiation therapy for inoperable early stage lung cancer.

The Lancet. Oncology, 2015-02

Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2009-07

Comprehensive analysis of pulmonary function Test (PFT) changes after stereotactic body radiotherapy (SBRT) for stage I lung cancer in medically inoperable patients.

Clin Lung Cancer, 2017 Jul 10

Impact of Pretreatment Interstitial Lung Disease on Radiation Pneumonitis and Survival in Patients Treated With Lung Stereotactic Body Radiation Therapy (SBRT).

International journal of radiation oncology, biology, physics, 2008-10-01

Baseline pulmonary function as a predictor for survival and decline in pulmonary function over time in patients undergoing stereotactic body radiotherapy for the treatment of stage I non-small-cell lung cancer.

Cancers (Basel), 2018 Aug 02

Stereotactic Body Radiation Therapy for Patients with Pulmonary Interstitial Change: High Incidence of Fatal Radiation Pneumonitis in a Retrospective Multi-Institutional Study.

The New England journal of medicine, 2012-06-14

Central-airway necrosis after stereotactic body-radiation therapy.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-10-20

Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer.

International journal of radiation oncology, biology, physics, 2012-08-01

Esophageal toxicity from high-dose, single-fraction paraspinal stereotactic radiosurgery.

International journal of radiation oncology, biology, physics, 2014-07-01

Predictors of rectal tolerance observed in a dose-escalated phase 1-2 trial of stereotactic body radiation therapy for prostate cancer.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2009-06

Central thoracic lesions treated with hypofractionated stereotactic body radiotherapy.

J Thorac Oncol, 2011 Dec

Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer.

International journal of radiation oncology, biology, physics, 2013-08-01

High-dose hypofractionated proton beam radiation therapy is safe and effective for central and peripheral early-stage non-small cell lung cancer: results of a 12-year experience at Loma Linda University Medical Center.

Radiother Oncol, 2011 Nov

Outcomes of stereotactic ablative radiotherapy following a clinical diagnosis of stage I NSCLC: comparison with a contemporaneous cohort with pathologically proven disease.

International journal of radiation oncology, biology, physics, 2010-03-01

Chest wall volume receiving >30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy.

Pract Radiat Oncol, 2019 Nov

Salvage Curative-Intent Reirradiation Stereotactic Body Radiation Therapy for Isolated Pelvic and/or Paraortic Recurrences of Gynecologic Malignancies.

The Journal of thoracic and cardiovascular surgery, 2013-03

Positron emission tomography combined with diagnostic chest computed tomography enhances detection of regional recurrence after stereotactic body radiation therapy for early stage non-small cell lung cancer.

Medical physics, 2013-09

Experimentally studied dynamic dose interplay does not meaningfully affect target dose in VMAT SBRT lung treatments.

International journal of radiation oncology, biology, physics, 2010-06-01

Intensity-modulated radiotherapy-based stereotactic body radiotherapy for medically inoperable early-stage lung cancer: excellent local control.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2009-08

A comparison of two stereotactic body radiation fractionation schedules for medically inoperable stage I non-small cell lung cancer: the Cleveland Clinic experience.

International journal of radiation oncology, biology, physics, 2007-10-01

Clinicopathologic analysis of microscopic extension in lung adenocarcinoma: defining clinical target volume for radiotherapy.

Int J Radiat Oncol Biol Phys, 2000 Nov 1

Evaluation of microscopic tumor extension in non-small-cell lung cancer for three-dimensional conformal radiotherapy planning.

Sarcoma, 2013

The use of radiation therapy in the management of selected patients with atypical lipomas.

Cancer, 1998 Mar 15

Focal, high dose, and fractionated modified stereotactic radiation therapy for lung carcinoma patients: a preliminary experience.

International journal of radiation oncology, biology, physics, 2012-11-01

Modeling local control after hypofractionated stereotactic body radiation therapy for stage I non-small cell lung cancer: a report from the elekta collaborative lung research group.

International journal of radiation oncology, biology, physics, 2017-03-15

Influence of Fractionation Scheme and Tumor Location on Toxicities After Stereotactic Body Radiation Therapy for Large (≥5 cm) Non-Small Cell Lung Cancer: A Multi-institutional Analysis.

International journal of radiation oncology, biology, physics, 2015-11-15

A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer: NRG Oncology RTOG 0915 (NCCTG N0927).

Radiother Oncol, 2013 Aug

Lung stereotactic body radiation therapy (SBRT) delivered over 4 or 11 days: a comparison of acute toxicity and quality of life.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2016-10

Local control dependence on consecutive vs. nonconsecutive fractionation in lung stereotactic body radiation therapy.

International journal of radiation oncology, biology, physics, 2016-12-01

The Effect of Biologically Effective Dose and Radiation Treatment Schedule on Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.

Practical radiation oncology, 2018

Local control for clinical stage I non-small cell lung cancer treated with 5-fraction stereotactic body radiation therapy is not associated with treatment schedule.

Radiation oncology (London, England), 2013-01-03

Stereotactic body radiation therapy for the treatment of early-stage minimally invasive adenocarcinoma or adenocarcnioma in situ (formerly bronchioloalveolar carcinoma): a patterns of failure analysis.

Cancer, 2007-11-15

Radiation therapy is associated with improved survival in patients with pancreatic adenocarcinoma: results of a study from the Surveillance, Epidemiology, and End Results (SEER) registry data.

Cancer, 2015-04-01

Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma.

JAMA, 2012 Jul 11

Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.

JAMA, 2008-03-05

Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-07-20

Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011-08-01

Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-07-20

Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005).

International journal of radiation oncology, biology, physics, 2011-09-01

Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer.

American journal of clinical oncology, 2011-02

Stereotactic body radiotherapy in the treatment of advanced adenocarcinoma of the pancreas.

International journal of radiation oncology, biology, physics, 2013-12-01

Mapping patterns of local recurrence after pancreaticoduodenectomy for pancreatic adenocarcinoma: a new approach to adjuvant radiation field design.

JAMA, 2007 Jan 17

Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.

Cancer, 1987 Jun 15

Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group.

Ann Surg, 2007 Nov

Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891.

International journal of radiation oncology, biology, physics, 2014-12-01

Local control and toxicity in a large cohort of central lung tumors treated with stereotactic body radiation therapy.

International journal of radiation oncology, biology, physics, 2014-04-01

Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a "no fly zone".

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2009-12

Brachial plexopathy from stereotactic body radiotherapy in early-stage NSCLC: dose-limiting toxicity in apical tumor sites.

International journal of radiation oncology, biology, physics, 2012-10-01

Development of a standardized method for contouring the lumbosacral plexus: a preliminary dosimetric analysis of this organ at risk among 15 patients treated with intensity-modulated radiotherapy for lower gastrointestinal cancers and the incidence of radiation-induced lumbosacral plexopathy.

Medical physics, 2010-08

Stereotactic body radiation therapy: the report of AAPM Task Group 101.

International journal of radiation oncology, biology, physics, 2009-07-01

Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas.

Journal of surgical oncology, 2014-08

Long-term results of Phase II study of high dose photon/proton radiotherapy in the management of spine chordomas, chondrosarcomas, and other sarcomas.

International journal of radiation oncology, biology, physics, 2015-06-01

Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer Tumors Greater Than 5 cm: Safety and Efficacy.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-01-10

Phase I study of accelerated conformal radiotherapy for stage I non-small-cell lung cancer in patients with pulmonary dysfunction: CALGB 39904.

J Natl Cancer Inst, 2014 Aug

Phase II study of accelerated hypofractionated three-dimensional conformal radiotherapy for stage T1-3 N0 M0 non-small cell lung cancer: NCIC CTG BR.25.

Frontiers in oncology, 2011

Six-Dimensional Correction of Intra-Fractional Prostate Motion with CyberKnife Stereotactic Body Radiation Therapy.

Eur Urol, 2015 Jul 16

Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-naive Recurrence: A Multi-institutional Analysis.

BJU Int, 2009 Feb

Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial.

European urology, 2014-06

Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study.

Int J Radiat Oncol Biol Phys, 2008 Oct 1

Stereotactic body radiotherapy for oligometastatic lung tumors.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-01-20

Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis.

Technology in cancer research & treatment, 2014-06

The effectiveness of a pneumatic compression belt in reducing respiratory motion of abdominal tumors in patients undergoing stereotactic body radiotherapy.

The Lancet. Oncology, 2015-06

Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-11-01

Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.

Semin Radiat Oncol, 2015 Oct

Predicting Radiotherapy Responses and Treatment Outcomes Through Analysis of Circulating Tumor DNA.

Journal of applied clinical medical physics, 2010-08-19

Portal dosimetry for pretreatment verification of IMRT plan: a comparison with 2D ion chamber array.

Technology in cancer research & treatment, 2016-02

Comparison of Ray Tracing and Monte Carlo Calculation Algorithms for Thoracic Spine Lesions Treated With CyberKnife-Based Stereotactic Body Radiation Therapy.

International journal of radiation oncology, biology, physics, 2012-01-01

Reirradiation human spinal cord tolerance for stereotactic body radiotherapy.

The Lancet. Oncology, 2015-12

Response assessment after stereotactic body radiotherapy for spinal metastasis: a report from the SPIne response assessment in Neuro-Oncology (SPINO) group.

International journal of radiation oncology, biology, physics, 2010-12-01

Stereotactic body radiation therapy for patients with lung cancer previously treated with thoracic radiation.

Frontiers in oncology, 2014

Safety and Tolerability of SBRT after High-Dose External Beam Radiation to the Lung.

Radiother Oncol, 2013 Oct

High-risk CT features for detection of local recurrence after stereotactic ablative radiotherapy for lung cancer.

International journal of radiation oncology, biology, physics, 2016-09-01

Validation of High-Risk Computed Tomography Features for Detection of Local Recurrence After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer.

Radiother Oncol, 2012 Mar

Radiographic changes after lung stereotactic ablative radiotherapy (SABR)--can we distinguish recurrence from fibrosis? A systematic review of the literature.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-12-01

Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer.

The Lancet. Oncology, 2016-12

Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study.

International journal of radiation oncology, biology, physics, 2015-09-01

Precision Hypofractionated Radiation Therapy in Poor Performing Patients With Non-Small Cell Lung Cancer: Phase 1 Dose Escalation Trial.

J Thorac Oncol, 2016-07-01

Outcomes of Hypofractionated High-Dose Radiotherapy in Poor-Risk Patients with "Ultracentral" Non-Small Cell Lung Cancer.

The British journal of radiology, 2016

The significance of PTV dose coverage on cancer control outcomes in early stage non-small cell lung cancer patients treated with highly ablative stereotactic body radiation therapy.

Int. J. Radiat. Oncol. Biol. Phys., 2006-02-01

Conformity index: a review.

International journal of radiation oncology, biology, physics, 2009-02-01

Conformity of LINAC-based stereotactic radiosurgery using dynamic conformal arcs and micro-multileaf collimator.

N Engl J Med, 2007 Aug 16

Prophylactic cranial irradiation in extensive small-cell lung cancer.

Lancet, 2015 Jan 3

Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial.

Clin Lung Cancer, 2011-11-01

Clinical outcomes of extensive stage small cell lung carcinoma patients treated with consolidative thoracic radiotherapy.

International journal of radiation oncology, biology, physics, 2016-08-01

Simple Factors Associated With Radiation-Induced Lung Toxicity After Stereotactic Body Radiation Therapy of the Thorax: A Pooled Analysis of 88 Studies.

Hematology/oncology clinics of North America, 2006-02

Intensity-modulated radiation therapy and image-guided radiation therapy: small clinic implementation.

Practical radiation oncology, 2014

Outcomes and toxicities of stereotactic body radiation therapy for non-spine bone oligometastases.

Ann Palliat Med, 2016 Jan

Stereotactic body radiation therapy for non-spine bone metastases--a review of the literature.

Clin Oncol (R Coll Radiol), 2015-05-01

Stereotactic body radiotherapy for spinal and bone metastases.

Cancer, 2010-05-01

Radiosurgical decompression of metastatic epidural compression.

Journal of pain and symptom management, 2008-03

Pain control by image-guided radiosurgery for solitary spinal metastasis.

Lancet (London, England), 2005

Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial.

JAMA oncology, 2018-01-11

Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-06-20

Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study.

J. Clin. Oncol., 2020 Jun 02

Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial.

Pract Radiat Oncol, 2020 Mar 11

Stereotactic Body Radiation Therapy for Nonspine Bone Metastases: International Practice Patterns to Guide Treatment Planning.

Int J Radiat Oncol Biol Phys, 2021 Sep 09

International Multi-institutional Patterns of Contouring Practice and Clinical Target Volume Recommendations for Stereotactic Body Radiation Therapy for Non-Spine Bone Metastases.

Clin. Cancer Res., 2020 Feb 13

A Phase II Trial of 5-Day Neoadjuvant Radiotherapy for Patients with High-Risk Primary Soft Tissue Sarcoma.

Frontiers in oncology, 2017

Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on 3-Year Toxicity.

International journal of radiation oncology, biology, physics, 2008-09-01

Intrafractional motion of the prostate during hypofractionated radiotherapy.

International journal of radiation oncology, biology, physics, 2014-11-15

Incidence and predictive factors of pain flare after spine stereotactic body radiation therapy: secondary analysis of phase 1/2 trials.

Int J Radiat Oncol Biol Phys, 2009 Sep 1

Determining the incidence of pain flare following palliative radiotherapy for symptomatic bone metastases: results from three canadian cancer centers.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-04-01

Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases.

Translational oncology, 2013-08

Stereotactic body radiation therapy for primary and metastatic liver tumors.

Acta Oncol, 2006-01-01

Phase II study on stereotactic body radiotherapy of colorectal metastases.

J. Cancer Res. Clin. Oncol., 2015-07-01

The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT).

Semin Radiat Oncol, 2017-07-01

Stereotactic Body Radiotherapy for Liver Metastases.

N Engl J Med, 2017 Nov 16

Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

International journal of radiation oncology, biology, physics, 2008-04-01

Virtual HDR CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations.

International journal of radiation oncology, biology, physics, 2016-07-01

Dose-Escalated Stereotactic Body Radiation Therapy for Patients With Intermediate- and High-Risk Prostate Cancer: Initial Dosimetry Analysis and Patient Outcomes.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2013-11

Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011-05-20

Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer.

Frontiers of radiation therapy and oncology, 2011

Stereotactic body radiotherapy for prostate cancer: current results of a phase II trial.

Int. J. Radiat. Oncol. Biol. Phys.,

A Phase 2 Randomized Study of 2 Stereotactic Body Radiation Therapy Regimens for Medically Inoperable Patients With Node-Negative, Peripheral Non-Small Cell Lung Cancer.

International journal of radiation oncology, biology, physics, 2009-04-01

Elective nodal irradiation for locally advanced non-small-cell lung cancer: it's called cancer for a reason.

Journal of neurosurgery. Spine, 2012-07

Single-session and multisession CyberKnife radiosurgery for spine metastases-University of Pittsburgh and Georgetown University experience.

International journal of radiation oncology, biology, physics, 2010-06-01

Spinal cord tolerance for stereotactic body radiotherapy.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-09-20

Vertebral compression fracture after spine stereotactic body radiotherapy: a multi-institutional analysis with a focus on radiation dose and the spinal instability neoplastic score.

Future oncology (London, England), 2015

Single versus multiple session stereotactic body radiotherapy for spinal metastasis: the risk-benefit ratio.

Future Oncol, 2015 Oct 15

Corrigendum.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-10-20

Risk of fracture after single fraction image-guided intensity-modulated radiation therapy to spinal metastases.

International journal of radiation oncology, biology, physics, 2014-09-01

Esophageal dose tolerance to hypofractionated stereotactic body radiation therapy: risk factors for late toxicity.

Clinical lung cancer, 2016-11

Stereotactic Body Radiotherapy for T3N0 Lung Cancer With Chest Wall Invasion.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2014-08

Stereotactic ablative radiotherapy (SABR) using 70 Gy in 10 fractions for non-small cell lung cancer: exploration of clinical indications.

International journal of radiation oncology, biology, physics, 2013-01-01

Brachial plexopathy in apical non-small cell lung cancer treated with definitive radiation: dosimetric analysis and clinical implications.

Annals of surgical oncology, 2002-07

Long-term complications associated with breast-conservation surgery and radiotherapy.

International journal of radiation oncology, biology, physics, 1992

Long-term radiation complications following conservative surgery (CS) and radiation therapy (RT) in patients with early stage breast cancer.

Clin Oncol (R Coll Radiol),

Long-term survival in patients with non-small cell lung cancer treated with palliative radiotherapy.

J Thorac Oncol,

Impact of pretreatment interstitial lung disease on radiation pneumonitis and survival after stereotactic body radiation therapy for lung cancer.

Clinical lung cancer, 2018-07

Fatal Radiation Pneumonitis in Patients With Subclinical Interstitial Lung Disease.

Int. J. Radiat. Oncol. Biol. Phys., 2017 Mar 15

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2016-06

Pre-treatment non-target lung FDG-PET uptake predicts symptomatic radiation pneumonitis following Stereotactic Ablative Radiotherapy (SABR).

Practical radiation oncology, 2018

Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO, and AUA Evidence-Based Guideline.

Practical radiation oncology, 2018

A multi-institutional phase 2 trial of prostate stereotactic body radiation therapy (SBRT) using continuous real-time evaluation of prostate motion with patient-reported quality of life.

Medical physics, 2011-11

The correlation of tissue motion within the lung: implications on fiducial based treatments.

Clin Lung Cancer, 2017 Mar

Canadian Phase III Randomized Trial of Stereotactic Body Radiotherapy Versus Conventionally Hypofractionated Radiotherapy for Stage I, Medically Inoperable Non-Small-Cell Lung Cancer - Rationale and Protocol Design for the Ontario Clinical Oncology Group (OCOG)-LUSTRE Trial.

International journal of radiation oncology, biology, physics, 2013-04-01

Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non-small cell lung cancer: a prospective study.

Practical radiation oncology, 2016

Fatal complications after stereotactic body radiation therapy for central lung tumors abutting the proximal bronchial tree.

N. Engl. J. Med.,

Radiation-induced splenic atrophy in patients with Hodgkin's disease and non-Hodgkin's lymphomas.

PLoS ONE, 2015 Nov 24

Spleen Volume Variation in Patients with Locally Advanced Non-Small Cell Lung Cancer Receiving Platinum-Based Chemo-Radiotherapy.

Lancet, 2019 Apr 11

Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial.

Cancer, 2011-09-01

Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis.

International journal of radiation oncology, biology, physics, 2015-07-01

Gastrointestinal Toxicities With Combined Antiangiogenic and Stereotactic Body Radiation Therapy.

Cancer treatment reviews, 2017-02

Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic review.

Strahlenther Onkol, 2019 Feb 08

Combination of stereotactic radiotherapy and targeted therapy: patterns-of-care survey in German-speaking countries.

Radiother Oncol, 2018 Jul 09

Stereotactic body radiotherapy for colorectal cancer liver metastases: A systematic review.

Clin Oncol (R Coll Radiol), 2017 Oct 13

UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy.

European urology focus, 2019-11

The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.

Adv Radiat Oncol, 2017 Nov 22

External beam radiation therapy for advanced/unresectable malignant paraganglioma and pheochromocytoma.

BMC Cancer, 2019 Aug 19

Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial.

Pract Radiat Oncol, 2020 Aug 10

Repeated Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma.

Stereotactic Body Radiotherapy

Questions discussed in this category

Papers discussed in this category

Related Topics